📣 VC round data is live. Check it out!
- Public Comps
- Syncona
Syncona Valuation Multiples
Discover Syncona's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like IP Group, NB Private Equity Partners, Kyobo Securities, Hanwha Investment and more.
Syncona Overview
About Syncona
Syncona Ltd is a closed-ended investment company in the United Kingdom. Its investment objective is to achieve superior long-term capital appreciation from its investments. The company invests in life science businesses (including private and quoted companies) and single or multi-asset projects (Life Science Investments).
Founded
2012
HQ

Employees
37
Website
Sectors
Financials (FY)
EV
$827M
Valuation Multiples
Start free trialSyncona Financials
Syncona reported last fiscal year revenue of $89M and EBITDA of $195M.
In the same fiscal year, Syncona generated $195M in EBITDA and had net loss of ($192M).
Revenue (LTM)
Syncona P&L
In the most recent fiscal year, Syncona reported revenue of $89M and EBITDA of $195M.
Syncona is unprofitable as of last fiscal year, with EBITDA margin of 218% and net margin of (215%).
Financial data powered by Morningstar, Inc.
Syncona Stock Performance
Syncona has current market cap of $827M, and enterprise value of $827M.
Market Cap Evolution
Syncona's stock price is $1.36.
Syncona share price increased by 0.2% in the last 30 days, and by 9.9% in the last year.
Syncona has an EPS (earnings per share) of $-0.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $827M | $827M | 0.3% | 0.2% | 13.2% | 9.9% | $-0.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSyncona Valuation Multiples
Syncona trades at 9.3x EV/Revenue multiple, and 4.2x EV/EBITDA.
EV / Revenue (LTM)
Syncona Financial Valuation Multiples
As of June 3, 2026, Syncona has market cap of $827M and EV of $827M.
Syncona has a P/E ratio of (4.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Syncona Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Syncona Margins & Growth Rates
In the most recent fiscal year, Syncona reported EBITDA margin of 218% and net margin of (215%).
Syncona Margins
Syncona Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Syncona Operational KPIs
Syncona's revenue per employee in the last FY averaged $2.4M, while opex per employee averaged $2.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Syncona Competitors
Syncona competitors include IP Group, NB Private Equity Partners, Kyobo Securities, Hanwha Investment, Treasure ASA, Eczacıbaşı Yatırım, Abacus Global Management, Amanat, Navigator Global and HMC Capital.
Most Syncona public comparables operate across PE & VC and Asset Management.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 8.1x | 9.3x | 12.0x | 12.1x | |||
| 20.0x | - | - | - | |||
| 2.7x | - | 3.1x | - | |||
| 2.6x | - | - | - | |||
| - | - | - | - | |||
| - | - | 43.9x | - | |||
| 4.9x | 4.6x | 8.5x | 8.0x | |||
| 2.5x | - | 5.8x | - | |||
This data is available for Pro users. Sign up to see all Syncona competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Syncona
Syncona has acquired 2 companies to date.
Last acquisition by Syncona was on November 22nd 2023. Syncona acquired Freeline for $28M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Syncona
| Description | Freeline is a London-based clinical-stage biotech company developing AAV gene therapies for rare liver disorders like hemophilia B. Its lead candidate, FLT201, entered Phase 1/2 trials in 2022 using a proprietary capsid for high liver tropism and sustained Factor IX expression at 50 percent normal levels. Freeline also advances programs for Fabry disease, with manufacturing in Stevenage, UK, and partnerships with Sarepta Therapeutics. Publicly traded until 2022 acquisition talks. | Applied Genetic Technologies Corporation is a clinical-stage biotechnology firm developing AAV-based gene therapies for retinal and neuromuscular diseases. Headquartered in Alachua, Florida, it advances programs like AGTC-501 for X-linked retinitis pigmentosa and rAAV2tYF-GRK1-RPGR for XLRP, conducting Phase 1/2 trials with FDA orphan drug designations. |
| HQ Country | ||
| HQ City | Stevenage | Alachua, FL |
| Deal Date | 22 Nov 2023 | 24 Oct 2022 |
| Valuation | $28M | $24M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Syncona acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by Syncona
Syncona has invested in 24 companies to date.
Latest investment by Syncona was on May 17th 2026. Syncona invested in Re-Aim Therapeutics in their $10M Seed round (EV/Revenue multiple available to Pro users).
Latest Investments by Syncona
| Description | Re-Aim Therapeutics is a UK-based biotechnology startup developing functional cures for T cell-mediated autoimmune diseases through selective depletion of pathogenic T-cell subsets. Its lead asset, REA-001, is a monoclonal antibody that targets type-17 T cells to reset immune response and support durable remission. | Beacon Therapeutics is a London-headquartered gene therapy company targeting inherited retinal diseases causing blindness. The firm advances GT005, an AAV-delivered therapy for wet AMD choroidal neovascularization, with Phase 2b trials ongoing in the United States and Europe following seed funding from Oxford Nanopore founders. | Apini Therapeutics is a UK-based biotech developing small-molecule drugs targeting IL-23 and TNF pathways for ulcerative colitis and Crohn's disease. The company's lead candidate, APN-01, advances through Phase II trials for moderate-to-severe IBD patients. Headquartered in Cambridge, Apini collaborates with contract research organizations in Europe. | Purespring Therapeutics is a biotech company developing AAV gene therapies for kidney diseases targeting podocytes. Oxford-based, it pioneers renal gene delivery platforms to treat conditions like focal segmental glomerulosclerosis. Backed by investors, Purespring advances preclinical programs toward clinical trials in collaboration with academic partners. | |
| HQ Country | |||||
| HQ City | Oxford | London | - | London | |
| Deal Date | 17 May 2026 | 8 Jan 2026 | 11 Jun 2025 | 9 Oct 2024 | |
| Round | Seed | Series C | Seed | Series B | |
| Raised | $10M | $75M | $3M | $103M | |
| Investors | Oxford Science Enterprises; Syncona | Advent Life Sciences; Forbion Capital Partners; Goldman Sachs Asset Management; Oxford Science Enterprises; Retinal Degeneration Fund; Syncona | Northern Gritstone; Syncona | British Patient Capital; Forbion Capital Partners; Gilde Healthcare; Sofinnova Partners; Syncona | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Syncona investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Syncona
| When was Syncona founded? | Syncona was founded in 2012. |
| Where is Syncona headquartered? | Syncona is headquartered in United Kingdom. |
| How many employees does Syncona have? | As of today, Syncona has over 37 employees. |
| Is Syncona publicly listed? | Yes, Syncona is a public company listed on London Stock Exchange. |
| What is the stock symbol of Syncona? | Syncona trades under SYNC ticker. |
| Who are competitors of Syncona? | Syncona main competitors include IP Group, NB Private Equity Partners, Kyobo Securities, Hanwha Investment, Treasure ASA, Eczacıbaşı Yatırım, Abacus Global Management, Amanat, Navigator Global, HMC Capital. |
| What is the current market cap of Syncona? | Syncona's current market cap is $827M. |
| What is the current revenue of Syncona? | Syncona's last fiscal year revenue is $89M. |
| What is the current EV/Revenue multiple of Syncona? | Current revenue multiple of Syncona is 9.3x. |
| Is Syncona profitable? | No, Syncona is not profitable. |
| How many companies Syncona has acquired to date? | As of June 2026, Syncona has acquired 2 companies. |
| What was the largest acquisition by Syncona? | $28M acquisition of Freeline on 22nd November 2023 was the largest M&A Syncona has done to date. |
| What companies Syncona acquired? | Syncona acquired Freeline and AGTC. |
| In how many companies Syncona has invested to date? | As of June 2026, Syncona has invested in 24 companies. |
| In what companies Syncona invested in? | Syncona invested in Beacon Therapeutics, Quell Therapeutics, Gyroscope Therapeutics, Achilles Therapeutics, Anaveon, Freeline, Neogene Therapeutics, Purespring Therapeutics, OMass Therapeutics, Clade Therapeutics, iOnctura, Autolus Therapeutics, SwanBio Therapeutics, Spur Therapeutics, Nightstar Therapeutics, Azeria Therapeutics, Resolution Therapeutics, Blue Earth Diagnostics, Mosaic Therapeutics, Kesmalea Therapeutics, and 4 other companies. |
See public comps similar to Syncona
Lists including Syncona
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

